catalog number :
MBS670057
products full name :
Rat Anti-Human G-CSF-UNLB
products short name :
G-CSF
products name syn :
Rat Anti-Human G-CSF - Purified, Unlabeled Antibody; Rat Anti-Human G-CSF
other names :
granulocyte colony-stimulating factor; Granulocyte colony-stimulating factor; granulocyte colony-stimulating factor; filgrastim; lenograstim; pluripoietin; OTTHUMP00000164325; OTTHUMP00000164326; OTTHUMP00000164327; OTTHUMP00000164328; colony stimulating factor 3 (granulocyte); Pluripoietin
other gene names :
CSF3; CSF3; GCSF; CSF3OS; C17orf33; MGC45931; C17orf33; GCSF
uniprot entry name :
CSF3_HUMAN
specificity :
Human Granulocyte-Colony Stimulating Factor (G-CSF)1, 2 (This is a neutralizing antibody)
form :
Purified (UNLB) Antibody
storage stability :
The purified (UNLB) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of 100 mM borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added. Store at 2- 8 degree C. The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. Aliquot and store at or below -20 degree C. Protect conjugated forms from light. Aliquot and freeze the low endotoxin, azide-free product at -20 degree C immediately upon receipt. Each reagent is stable for the period shown on the bottle label if stored as directed.
tested application :
ELISA; Western Blot
app notes :
Research Application(s): ELISA Capture: BVD13-3A5 monoclonal antibody is useful as a capture antibody in a sandwich ELISA for quantifying human G-CSF protein levels.1, 2 Purified BVD13-3A5 antibody should be paired with biotinylated BVD11-37G10 antibody as the detection antibody, with purified recombinant human G-CSF as the standard. Western Blotting: The purified BVD13-3A5 antibody is also useful for Western blotting applications. A concentration of 1-5 ug/mL (in conjunction with AP-labeled Goat Anti-Rat-Ig) has been found to enable detection of <= 100 ng/lane of recombinant human G-CSF under reducing conditions. Neutralization: The LE/AF form of BVD13-3A5 can be used for neutralizing human G-CSF bioactivity. A suitable LE/AF Rat IgG1 should be used as an isotype control. Since applications vary, each investigator should determine the optimal concentration appropriate for individual applications.
other info1 :
Immunogen: E. coli-expressed recombinant human G-CSF
other info2 :
Characterization: To ensure acceptable performance, each batch of product is tested in a sandwich ELISA to conform to characteristics of a standard reference reagent.
products references :
1. Abrams, J. 1995. Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies. In Current Protocols in Immunology (J. Coligamn, A. Kruisbeek, D. Margulies, E. Shevach, W. Strober, eds.). John Wiley and Sons, New York. Unit 6.20. 2. Abrams, J.S., M.-G. Roncarolo, H. Yssel, U. Andersson, G.J. Gleich, and J.E., Silver. 1992. Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol. Rev. 127:5-24.
ncbi mol weight :
22,293 Da
ncbi pathways :
Cytokine-cytokine Receptor Interaction Pathway 83051!!Cytokine-cytokine Receptor Interaction Pathway 460!!Cytokines And Inflammatory Response Pathway 198794!!Hematopoietic Cell Lineage Pathway 83078!!Hematopoietic Cell Lineage Pathway 489!!Jak-STAT Signaling Pathway 83077!!Jak-STAT Signaling Pathway 488!!Malaria Pathway 152665!!Malaria Pathway 152657
ncbi summary :
The protein encoded by this gene is a cytokine that controls the production, differentiation, and function of granulocytes. The active protein is found extracellularly. Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq]
uniprot summary :
Function: Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes. Subunit structure: Monomer. Subcellular location: Secreted. Post-translational modification: O-glycan consists of Gal-GalNAc disaccharide which can be modified with up to two sialic acid residues (done in recombinantly expressed G-CSF from CHO cells). Pharmaceutical use: Available under the names Neupogen or Granulokine (Amgen/Roche) and Granocyte (Rhone-Poulenc). Used to treat neutropenia (a disorder characterized by an extremely low number of neutrophils in blood). Sequence similarities: Belongs to the IL-6 superfamily. Caution: Ref.5 misquotes the gene name as "CSF1".